Company Update (NYSE MKT:ISR): Isoray, Inc.’s Intra-Cranial Brachytherapy Brain Cancer Treatments Utilizing Cesium-131 were Presented at the Brain Tumor Biotech Summit 2015

IsoRay, Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications; announced it presented last Friday at the Brain Tumor Biotech Summit 2015. William Cavanagh, VP R&D of IsoRay Medical, shared published results and major medical institutions’ experiences to date utilizing Cesium-131 for brain tumors.

The Brain Tumor Biotech Summit brings together the nation’s top cancer specialists, biotechnology companies, the pharmaceutical industry and the investment community to promote innovative new therapies for brain tumors.

The Brain Tumor Biotech Summit was sponsored by the Brain Tumor Biotech Center at The Feinstein Institute for Medical Research and Voices Against Brain Cancer. IsoRay CEO Dwight Babcock commented, “The Company is pleased to have been invited to present at this prestigious event as it provides a forum to share the success Cesium-131 is having in threating cancers of the brain. With our broader reach and our newly published study results, the medical community is becoming more aware of the innovative alternative our Cesium-131 products can offer to patients.”

IsoRay’s various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite® radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay’s cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life.

IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).

In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh. IsoRay also sells several new implantable devices, including the GliaSite® radiation therapy system. (Original Source)

Shares of IsoRay Inc opened today at $1.79 and are currently trading down at $1.72. ISR has a 1-year high of $3.79 and a 1-year low of $1.22. The stock’s 50-day moving average is $1.69 and its 200-day moving average is $1.57.

On the ratings front, Maxim Group analyst Jason Kolbert reiterated a Buy rating on ISR, with a price target of $5, in a report issued on May 21. The current price target implies an upside of 190.7% from current levels.

According to, Kolbert has a total average return of 3.2%, a 43.5% success rate, and is ranked #1074 out of 3610 analysts.

IsoRay Inc offers solutions for the treatment and diagnosis of disease using medical isotopes.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts